ArticleChaos (Woodbury, N.Y.)2020
Topological analysis of SARS CoV-2 main protease.
Article in Chaos (Woodbury, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 MScientific reports · 2025Article
- Physics-Based Protein Networks Might Recover Effectful Mutations─a Case Study on Cathepsin G.The journal of physical chemistry. B · 2024Article
- Allosteric Communication of the Dimerization and the Catalytic Domain in Photoreceptor Guanylate Cyclase.Biochemistry · 2024Article
- Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.Chemico-biological interactions · 2022Article
- Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.Journal of biomolecular structure & dynamics · 2022Article
- AnJournal of biomolecular structure & dynamics · 2022Article
- Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.Chemical reviews · 2022Review
- Comprehensive fitness landscape of SARS-CoV-2 MeLife · 2022Article
- Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.Journal of biomolecular structure & dynamics · 2022Article
- Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease.Bioorganic chemistry · 2021Article
- Comparative protein structure network analysis on 3CLProteins · 2021Article
- Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study.Arabian journal of chemistry · 2021Article
- Reducing SARS-CoV-2 pathological protein activity with small molecules.Journal of pharmaceutical analysis · 2021Review
- Review of COVID-19 Antibody Therapies.Annual review of biophysics · 2021Article
- Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?European journal of medicinal chemistry · 2021Review
- Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants.Communications biology · 2021Article
- Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.3 Biotech · 2021Article
- Mathematical modeling applied to epidemics: an overview.The Sao Paulo journal of mathematical sciences · 2021Article
- pyProGA-A PyMOL plugin for protein residue network analysis.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an urgent necessity of effective medication against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), which is producing the COVID-19 pandemic across the world. Its main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.